X4 Pharmaceuticals (NASDAQ:XFOR) Stock: Insider David Kirske Sells 11,767 Shares

Key Points

• CFO David Kirske sold 11,767 X4 Pharmaceuticals shares at an average price of $2.86, totaling $33,653.62 and reducing his ownership by 7.01% to 155,983 shares.
• X4 shares rose 2.5% to $2.90, but remain near their one-year low of $2.73 and below their 50-day and 200-day moving averages. The company reported better-than-expected quarterly results, with an EPS loss of $0.13 versus the expected $0.18 loss and revenue of $8.81 million.
• Analysts maintain a consensus “Moderate Buy” rating with an $11.25 price target, while institutional investors own 72.03% of the stock. X4’s key product is FDA-approved XOLREMDI, developed for WHIM syndrome.

X4 Pharmaceuticals, Inc. (NASDAQ:XFOR - Get Free Report) CFO David Kirske sold 11,767 shares of the firm's stock in a transaction on Thursday, October 1st. The shares were sold at an average price of $2.86, for a total value of $33,653.62. Following the transaction, the chief financial officer owned 155,983 shares of the company's stock, valued at $446,111.38. The trade was a 7.01% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

X4 Pharmaceuticals Stock Up 2.5%

X4 Pharmaceuticals stock traded up $0.07 during mid-day trading on Monday, reaching $2.90. The stock had a trading volume of 698,082 shares, compared to its average volume of 640,364. The company has a market capitalization of $287.54 million, a price-to-earnings ratio of -2.42 and a beta of 0.46. The company has a 50-day moving average price of $3.81 and a two-hundred day moving average price of $3.98. X4 Pharmaceuticals, Inc. has a one year low of $2.73 and a one year high of $4.83. The company has a debt-to-equity ratio of 0.49, a current ratio of 11.30 and a quick ratio of 11.02.

X4 Pharmaceuticals (NASDAQ:XFOR - Get Free Report) last released its quarterly earnings data on Thursday, August 6th. The company reported ($0.13) earnings per share for the quarter, beating analysts' consensus estimates of ($0.18) by $0.05. The business had revenue of $8.81 million during the quarter, compared to analyst estimates of $2.42 million. X4 Pharmaceuticals had a negative net margin of 568.80% and a negative return on equity of 63.05%. On average, analysts expect that X4 Pharmaceuticals, Inc. will post -0.67 EPS for the current fiscal year.

Hedge Funds Weigh In On X4 Pharmaceuticals

A number of institutional investors have recently bought and sold shares of the stock. Empery Asset Management LP bought a new stake in X4 Pharmaceuticals during the fourth quarter valued at about $35,804,000. Perceptive Advisors LLC grew its stake in shares of X4 Pharmaceuticals by 6.7% during the 1st quarter. Perceptive Advisors LLC now owns 6,737,648 shares of the company's stock valued at $27,826,000 after acquiring an additional 423,196 shares during the period. Bank of New York Mellon Corp purchased a new stake in X4 Pharmaceuticals in the 2nd quarter worth approximately $917,000. Bank of America Corp DE raised its stake in X4 Pharmaceuticals by 321.3% during the 1st quarter. Bank of America Corp DE now owns 150,676 shares of the company's stock worth $622,000 after acquiring an additional 114,915 shares during the period. Finally, Squarepoint Ops LLC bought a new stake in X4 Pharmaceuticals during the 2nd quarter worth approximately $313,000. 72.03% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several research firms have recently weighed in on XFOR. Wells Fargo & Company started coverage on X4 Pharmaceuticals in a report on Friday, July 10th. They set an "overweight" rating and a $11.00 price target on the stock. Weiss Ratings upgraded X4 Pharmaceuticals from a "sell (e+)" rating to a "sell (d-)" rating in a research report on Friday. Four research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, X4 Pharmaceuticals presently has an average rating of "Moderate Buy" and a consensus price target of $11.25.

X4 Pharmaceuticals Company Profile

X4 Pharmaceuticals, Inc is a biopharmaceutical company focused on developing and commercializing therapies for rare diseases caused by immune and hematologic dysfunction. The company's research centers on the CXCR4 biological pathway, which regulates the movement and retention of certain immune cells in the bone marrow and other tissues.

X4's primary product is XOLREMDI (mavorixafor), an oral CXCR4 antagonist approved by the U.S. Food and Drug Administration in 2024 for use in people aged 12 and older with WHIM syndrome.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.